Table.
Baseline demographics of the study participants
| Median age, years (range) | Median bodyweight, kg (range) | BMI, kg/m2 (range) | Sex, female:male ratio (%) | |
|---|---|---|---|---|
| Group 1A (n=3) | 31·0 (21·0–35·0) | 79·0 (61·0–96·0) | 23·0 (22·1–31·0) | 2:1 (67%) |
| Group 1B (n=3) | 27·0 (22·0–52·0) | 66·0 (59·0–69·6) | 22·4 (18·4–24·4) | 3:0 (100%) |
| Group 2A (n=3) | 25·0 (23·0–34·0) | 78·0 (76·0–89·4) | 26·0 (24·9–32·1) | 2:1 (67%) |
| Group 2B (n=3) | 37·0 (22·0–37·0) | 88·0 (62·0–94·0) | 24·9 (22·8–28·4) | 1:2 (33%) |
| Group 3A (n=3) | 27·0 (22·0–28·0) | 70·1 (61·2–79·0) | 23·6 (20·5–25·4) | 2:1 (67%) |
| Group 3B (n=3) | 48·0 (33·0–54·0) | 81·0 (72·8–91·0) | 26·4 (24·9–26·9) | 2:1 (67%) |
| Group 4 (n=6) | 25·5 (20·0–44·0) | 75·0 (60·0–97·0) | 25·0 (17·5–27·3) | 4:2 (67%) |
| Group 5 (n=6) | 20·5 (20·0–46·0) | 77·5 (66·0–90·0) | 23·7 (20·5–26·6) | 3:3 (50%) |
| Group 6 (n=9) | 24·0 (21·0–45·0) | 76·6 (61·0–91·0) | 23·3 (20·4–29·9) | 4:5 (44%) |
| Group 7 (n=6) | 24·0 (18·0–29·0) | 69·5 (60·0–88·0) | 24·5 (20·5–27·1) | 3:3 (50%) |
| Overall (n=45) | 26·0 (18·0–54·0) | 76·0 (59·0–97·0) | 24·2 (17·5–32·1) | 26:19 (58%) |
Doses of study groups were 6 μg ABNCoV2 in group 1A, 6 μg ABNCoV2 + MF59 in group 1B, 12 μg ABNCoV2 in group 2A, 12 μg ABNCoV2 + MF59 in group 2B, 25 μg ABNCoV2 in group 3A, 25 μg ABNCoV2 + MF59 in group 3B, 50 μg ABNCoV2 in group 4, 70 μg ABNCoV2 in group 5, 25 μg ABNCoV2 in group 6, and 50 μg ABNCoV2 in group 7.